Preview

Злокачественные опухоли

Расширенный поиск

СОВРЕМЕННЫЕ ТЕНДЕНЦИИ В ТЕРАПИИ УВЕАЛЬНОЙ МЕЛАНОМЫ: ОБЗОР ПРОБЛЕМЫ

https://doi.org/10.18027/2224-5057-2014-4-54-61

Полный текст:

Аннотация

Увеальная меланома — опухоль нейроэктодермального происхождения, развивающаяся из меланоцитов увеального тракта (хориоидеи, цилиарного тела, радужки). Это заболевание является редкой разновидностью меланомы, составляя приблизительно 3,5% от всех зарегистрированных случаев меланомы. И если в лечении метастатической меланомы  кожи уже достигнуты значительные  успехи, созданы  и зарегистрированы ингибиторы тирозинкиназ BRAF и MEK (вемурафениб, дабрафениб, траметиниб и др.) и моноколональные антитела для блокирования CTLA-4, PD-1 и PD-L1 (ипилимумаб, ламбролизумаб, ниволумаб и др.), то для увеальной меланомы активно ведут поиск новых мишеней направленной противоопухолевой терапии.

Об авторах

В. В. Назарова
Российский онкологический научный центр им. Н. Н. Блохина
Россия

Контактная информация: Назарова Валерия Витальевна — врач-онколог, аспирант отделения биотерапии опухолей РОНЦ им. Н.Н. Блохина, e-mail: jezerovel@gmail.com



К. В. Орлова
Российский онкологический научный центр им. Н. Н. Блохина
Россия
Орлова Кристина Вячеславовна — врач-онколог отделения биотерапии опухолей РОНЦ им. Н.Н. Блохина.


И. А. Утяшев
Российский онкологический научный центр им. Н. Н. Блохина
Россия
Утяшев Игорь Аглямович — научный сотрудник отделения биотерапии опухолей РОНЦ им. Н.Н. Блохина.


Н. Н. Мазуренко
Российский онкологический научный центр им. Н. Н. Блохина
Россия

Мазуренко Наталья Николаевна — профессор, заведующая лабораторией онкогеномики РОНЦ им. Н.Н. Блохина. 



Л. В. Демидов
Российский онкологический научный центр им. Н. Н. Блохина
Россия

Демидов Лев Вадимович — профессор, заведующий отделением биотерапии опухолей РОНЦ им. Н.Н. Блохина.



Список литературы

1. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011; 118:1881–1885; Epub 2011/06/28.

2. Gallanger R. P., Elwood J. M., Rootman (1985). Risk factors for ocular melanoma Western CanadanMelanoma Study, Natl cancer Inst, Vol 74, 775–778.

3. Sisley K., Rennie IG, Parsons MA, et.al Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis, Genes Chromosomes Cancer, 1997, 22–28.

4. Shah CP, Weis E, Lajous M, et al. Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis. Ophthalmology 2005; 112:1599–1607; Epub 2005/07/30.

5. Zuidervaart W, van Nieuwpoort F, Stark M, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005; 92:2032–2038; Epub 2005/06/02.

6. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010 [Epub 2010/11/19].

7. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457:599–602; Epub 2008/12/17.

8. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010 [Epub 2010/11/19].

9. Bauer J, Kilic E, Vaarwater J, et al. Oncogenic GNAQ mutations are not correlated with diseasefree survival in uveal melanoma. Br J Cancer 2009; 101:813–815; Epub 2009/08/06.

10. Singh AD, Rennie IG, Seregard S, et al. Sunlight exposure and pathogenesis of uveal melanoma. Survey Ophthalmol 2004; 49:419–428; Epub 2004/07/03.

11. All-Ericsson C, Girnita L, Seregard S, et al. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 2002; 43:1–8; Epub 2002/01/05.

12. Economou MA, All-Ericsson C, Bykov V, et al. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci 2005; 46:4372–4375; Epub 2005/11/24.

13. Mallikarjuna K, Pushparaj V, Biswas J, Krishnakumar S. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study. Curr Eye Res 2007; 32:281–290; Epub 2007/04/25.

14. Petrausch U, Martus P, Tonnies H, et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) 2008; 22:997–1007.

15. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64:7205–7209; Epub 2004/10/20.

16. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330:1410–1413; Epub 2010/11/06.

17. Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Institute 1990; 82:1765–1769.

18. Penel N, Delcambre C, Durando X, et al. O-Mel-Inib: a Cancero-pole Nord-Ouest multicenterphase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Investig New Drugs 2008; 26:561–565; Epub 2008/06/14.

19. Hofmann UB, Kauczok-Vetter CS, Houben R, Becker JC. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res 2009; 15:324–329; Epub 2009/01/02.

20. Wallender et al. Mod Pathol. 2011 Aug; 24 (8):1031–5.

21. Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res 2010; 16:6083–6092; Epub 2010/10/27.

22. Petrausch U, Martus P, Tonnies H, et al. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) 2008; 22:997–1007.

23. Tschentscher F, Husing J, Holter T, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003; 63:2578–2584; Epub 2003/05/17.

24. Onken MD, Worley LA, Harbour JW. Association between gene expression profile, proliferation and metastasis in uveal melanoma. Curr Eye Res 2010; 35:857–863; Epub 2010/08/28.

25. Shields CL, Ganguly A, Bianciotto CG, et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 2011; 118:396–401; Epub 2010/09/28.

26. Onken MD, Ehlers JP, Worley LA, et al. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res 2006; 66:4602–4609; Epub 2006/05/03.

27. Scholes AG, Damato BE, Nunn J, et al. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 2003; 44:1008–1011; Epub 2003/02/26.

28. Damato B, Eleuteri A, Taktak AF, Coupland SE. Estimating prognosis for survival after treatment of choroidal melanoma. Progress in retinal and eye research 2011; 30:285–295; Epub 2011/06/11.

29. Caujolle JP, Mammar H, Chamorey E, et al. Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years’ experience. Int J Radiat Oncol Biol Phys 2010; 78:98–103; Epub 2009/11/17.

30. Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C, et al. Treatment of uveal melanoma by accelerated proton beam. Develop Ophthalmol 2012; 49:41–57; Epub 2011/11/02.

31. Damato B, Eleuteri A, Taktak AF, Coupland SE. Estimating prognosis for survival after treatment of choroidal melanoma. Progress in retinal and eye research 2011; 30:285–295; Epub 2011/06/11.

32. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 2005; 123:1639–1643; Epub 2005/12/14.

33. Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009; 148:119–127; Epub 2009/04/21.

34. Orcurto V, Denys A, Voelter V, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in patients with liver metastases from uveal melanoma: results from a pilot study. Melanoma Res 2011 [Epub 2011/10/27].

35. Servois V, Mariani P, Malhaire C, et al. Preoperative staging of liver metastases from uveal melanoma by magnetic resonance imaging (MRI) and fluorodeoxyglucose-positron emission tomography (FDG-PET). Eur J Surg Oncol 2010; 36:189–194; Epub 2009/09/25.

36. Lane AM, Egan KM, Harmon D, et al. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology 2009; 116:2206–2212; Epub 2009/09/12.

37. Voelter V, Schalenbourg A, Pampallona S, et al. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients. Melanoma Res 2008; 18:220–224; Epub 2008/05/15.

38. Kivela T, Eskelin S, Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin 2006; 46:133–149; Epub 2005/12/21.

39. Mariani P, Piperno-Neumann S, Servois V, et al. Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie. Eur J Surg Oncol 2009; 35:1192–1197; Epub 2009/03/31.

40. Frenkel S, Nir I, Hendler K, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 2009; 93:1042–1046; Epub 2009/05/12.

41. Mavligit GM, Charnsangavej C, Carrasco CH, et al. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. J Am Med Assoc 1988; 260:974–976.

42. Huppert PE, Fierlbeck G, Pereira P, et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol 2010; 74: e38–44; Epub 2009/05/27.

43. Schuster R, Lindner M, Wacker F, et al. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res 2010; 20:191–196; Epub 2010/03/26.

44. Dayani PN, Gould JE, Brown DB, et al. Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization. Arch Ophthalmol 2009; 127:628–632; Epub 2009/05/13.

45. Vogl T, Eichler K, Zangos S, et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol 2007; 133:177–184; Epub 2006/10/06.

46. Sato T, Eschelman DJ, Gonsalves CF, et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2008; 26:5436–5442; Epub 2008/10/08.

47. Yamamoto A, Chervoneva I, Sullivan KL, et al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology 2009; 252:290–298; Epub 2009/06/30.

48. Fiorentini G, Aliberti C, Del Conte A, et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo 2009; 23:131–137; Epub 2009/04/17.

49. Richard D. Carvajal еt al. Phase II study of selumetinib versus temozolomide in Gnaq/Gna11 mutant uveal melanoma Clin Oncol 31, 2013 (suppl; abstr CRA9003)

50. Kennedy AS, Nutting C, Jakobs T, et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 2009; 27:682–690; Epub 2009/02/17.

51. Gonsalves CF, Eschelman DJ, Sullivan KL, et al. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. Am J Roentgenol 2011; 196:468–473; Epub 2011/01/25.

52. Richard D. Carvajal еt al. effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 2014 jun 18, 311 (23):2397–405. Doi: 10/1001/ jama.2014.6096.

53. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005; 23:3465–3474; Epub 2005/05/24.

54. Pingpank JF, Hughes MS, Faries MB, et al. A phase III random assignment trials comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. J Clin Oncol 2010; 28 (suppl; abstr LBA8512):18s.

55. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76:1665–1670.

56. Pons F, Plana M, Caminal JM, et al. Metastatic uveal melanoma: is there a role for conventional chemotherapy? A single center study based on 58 patients. Melanoma Res 2011; 21:217–222; Epub 2011/04/07.

57. Schmittel A, Schmidt-Hieber M, Martus P, et al. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol 2006; 17:1826–1829; Epub 2006/09/15.

58. Chan KR, Gundala S, Laudadio M, et al. A pilot study using sunitinib malate as therapy in patients with stage IV uveal melanoma. J Clin Oncol 2008; 26.

59. Kimple AJ, Bosch DE, Giguere PM, Siderovski DP. Regulators of G-protein signaling and their Galpha substrates: promises and challenges in their use as drug discovery targets. Pharmacol Rev 2011; 63:728–749; Epub 2011/07/09.

60. Ardjomand N, Schaffler G, Radner H, El-Shabrawi Y. Expression of somatostatin receptors in uveal melanomas. Invest Ophthalmol Vis Sci 2003; 44:980–987; Epub 2003/02/26.

61. Van Der Velden PA, De Lange M, Da Silva CG, et al. C–Met signaling and preclinical analysis of Crizotinib in uveal melanoma. Acta Ophthalmol 2011; 89.

62. Leyvraz S, Keilholz U. Ocular melanoma: what’s new? Curr Opin Oncol 2012; 24 (2):162–169.


Для цитирования:


Назарова В.В., Орлова К.В., Утяшев И.А., Мазуренко Н.Н., Демидов Л.В. СОВРЕМЕННЫЕ ТЕНДЕНЦИИ В ТЕРАПИИ УВЕАЛЬНОЙ МЕЛАНОМЫ: ОБЗОР ПРОБЛЕМЫ. Злокачественные опухоли. 2014;(4):54-61. https://doi.org/10.18027/2224-5057-2014-4-54-61

For citation:


Nazarova V.V., Orlova K.V., Utyashev I.A., Mazurenko N.N., Demidov L.V. Current trends in therapy of uveal melanoma: review of the problem. Malignant tumours. 2014;(4):54-61. (In Russ.) https://doi.org/10.18027/2224-5057-2014-4-54-61

Просмотров: 956


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)